BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/24/2020 2:27:20 AM | Browse: 680 | Download: 1020
 |
Received |
|
2020-02-27 06:51 |
|
Peer-Review Started |
|
2020-02-27 06:52 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-04-25 21:29 |
|
Revised |
|
2020-06-02 13:50 |
|
Second Decision |
|
2020-08-11 06:11 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-08-16 15:19 |
|
Articles in Press |
|
2020-08-16 15:19 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-08-22 10:28 |
|
Typeset the Manuscript |
|
2020-10-09 03:06 |
|
Publish the Manuscript Online |
|
2020-10-24 02:27 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Apatinib as an alternative therapy for advanced hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xi-Hao Zhang, Man-Qing Cao, Xiu-Xiu Li and Ti Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ti Zhang, MD, Professor, Surgical Oncologist, Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, No. 24 Bin Shui Road, Tianjin 300060, China. zhangti@tjmuch.com |
| Key Words |
Apatinib; Hepatocellular carcinoma; Angiogenesis; Vascular endothelial growth factor receptor 2; ; |
| Core Tip |
Apatinib, as a tyrosine kinase inhibitor, has a good inhibitory effect on advanced hepatocellular carcinoma (HCC). In this article, we will introduce the role of apatinib in advanced HCC from the aspects of structure and mechanism, pharmacokinetics, preclinical studies, clinical trials, side effects, and combined drug use. |
| Publish Date |
2020-10-24 02:27 |
| Citation |
Zhang XH, Cao MQ, Li XX, Zhang T. Apatinib as an alternative therapy for advanced hepatocellular carcinoma. World J Hepatol 2020; 12(10): 766-774 |
| URL |
https://www.wjgnet.com/1948-5182/full/v12/i10/766.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v12.i10.766 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
